AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17888161 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored worksite health promotion programme.
Number of subjects: 0
Study 15390018 — intervention group
Group type: EXPERIMENTAL
Intervention: NS 2330
Number of subjects: 9
Study 15390018 — intervention group
Group type: EXPERIMENTAL
Intervention: NS 2330 with levodopa
Number of subjects: 9
Study 15390018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11289350 — intervention group
Group type: EXPERIMENTAL
Intervention: T4N5 liposome lotion
Number of subjects: 30
Study 11289350 — intervention group
Group type: COMPARATOR
Intervention: Placebo liposome lotion
Number of subjects: 30
Study 9679359 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (AcuSlim device attached to acupuncture ear points shenmen and stomach)
Number of subjects: 60
Study 9679359 — intervention group
Group type: COMPARATOR
Intervention: Control group (AcuSlim device attached to thumb)
Number of subjects: 60
Study 8018006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin calcium ointment
Number of subjects: 68
Study 2920497 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive control dosing of etoposide (dose adjustment at 28 hours based on 24-hour plasma level)
Number of subjects: 31
Study 2920497 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of etoposide (125 mg/m2/day)
Number of subjects: 31
Study 30212951 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral ibuprofen (10, 5, and 5 mg/kg from days 1 to 3 after birth)
Number of subjects: 0
Study 30212951 — intervention group
Group type: COMPARATOR
Intervention: Conventional ibuprofen treatment (same dosage from days 4 to 6 after echocardiographic confirmation of PDA on day 3)
Number of subjects: 0
Study 30212951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% glucose)
Number of subjects: 0
Study 28106306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise plus acupuncture
Number of subjects: 227
Study 28106306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise plus electro-acupuncture
Number of subjects: 227
Study 28106306 — intervention group
Group type: COMPARATOR
Intervention: Group exercise (control)
Number of subjects: 227
Study 26220293 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed plasma (TP) administered in-field (2 units)
Number of subjects: 210
Study 26220293 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed plasma (TP)
Number of subjects: 210
Study 26220293 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 210
Study 23935129 — intervention group
Group type: EXPERIMENTAL
Intervention: 40,000 IU vitamin D/week for 6 months
Number of subjects: 0
Study 20300016 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arg/L-Orn supplementation
Number of subjects: 17
Study 20300016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 20300016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 17
Study 17715466 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised vestibular rehabilitation programme designed by a physiotherapist
Number of subjects: 32
Study 17715466 — intervention group
Group type: COMPARATOR
Intervention: Strength and endurance exercises only (Control)
Number of subjects: 32
Study 17196132 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg once a day for 12 weeks, followed by 36 weeks of ADV
Number of subjects: 230
Study 17196132 — intervention group
Group type: COMPARATOR
Intervention: Placebo once a day for 12 weeks, followed by 36 weeks of ADV
Number of subjects: 230
Study 17196132 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (LMV) 100 mg + Adefovir dipivoxil (ADV) 10 mg once a day for 12 weeks, followed by 36 weeks of ADV
Number of subjects: 230
Study 17196132 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LMV) 100 mg + Placebo once a day for 12 weeks, followed by 36 weeks of ADV
Number of subjects: 230
Study 17196132 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 230
Study 17196132 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine levels
Number of subjects: 230
Study 15333417 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130 (10 mL/kg IV for 30 min)
Number of subjects: 0
Study 15333417 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200 (10 mL/kg IV for 30 min)
Number of subjects: 0
Study 15333417 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (10 mL/kg IV for 30 min)
Number of subjects: 0
Study 15333417 — intervention group
Group type: EXPERIMENTAL
Intervention: All test infusions (HES 130, HES 200, Lactated Ringer's)
Number of subjects: 0
Study 11552898 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists
Number of subjects: 22
Study 11552898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9266259 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 59
Study 9266259 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous G-CSF substitution protocols
Number of subjects: 59
Study 8388285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine suspension 200 mg
Number of subjects: 60
Study 8388285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3712165 — intervention group
Group type: COMPARATOR
Intervention: Group 1: 2.24 gm/kg/day protein and 115 kcal/kg/day energy
Number of subjects: 0
Study 3712165 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 3.6 gm/kg/day protein and 115 kcal/kg/day energy
Number of subjects: 0
Study 3712165 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: 3.5 gm/kg/day protein and 149 kcal/kg/day energy
Number of subjects: 0
Study 29576347 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics treatment for intestinal pathogens
Number of subjects: 47
Study 29576347 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of stool pathogens after clinical stabilization
Number of subjects: 47
Study 29576347 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of stool pathogens
Number of subjects: 47
Study 26612275 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews during pregnancy and 4 times postpartum
Number of subjects: 10
Study 26612275 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 10
Study 25325491 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 335
Study 22537070 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/d BSP
Number of subjects: 81
Study 22537070 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/d BSP
Number of subjects: 81
Study 22537070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 20458453 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapydan patch (lidocaine-tetracaine)
Number of subjects: 200
Study 20458453 — intervention group
Group type: COMPARATOR
Intervention: EMLA patch (lidocaine-prilocaine)
Number of subjects: 200
Study 19119431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib polysaccharide conjugated to the tetanus toxoid (PRP-T)
Number of subjects: 319
Study 19119431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib polysaccharide conjugated to the outer‐membrane protein of Neisseria meningitides (PRP-OMP)
Number of subjects: 319
Study 16448551 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (5-FU, cisplatin, carboplatin, mitomycin C) with radiotherapy (RT)
Number of subjects: 10225
Study 16448551 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU with RT
Number of subjects: 10225
Study 16448551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy with RT
Number of subjects: 10225
Study 16448551 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-based chemotherapy with RT
Number of subjects: 10225
Study 16448551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C-based chemotherapy with RT
Number of subjects: 10225
Study 16448551 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy (HFRT)
Number of subjects: 10225
Study 16448551 — intervention group
Group type: COMPARATOR
Intervention: Accelerated radiotherapy (AFRT)
Number of subjects: 10225
Study 14661322 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.06 mg/kg
Number of subjects: 60
Study 14661322 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.12 mg/kg
Number of subjects: 60
Study 14661322 — intervention group
Group type: COMPARATOR
Intervention: Luminal 3 mg/kg
Number of subjects: 60
Study 11032592 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term tamoxifen treatment (12-13 years)
Number of subjects: 3793
Study 11032592 — intervention group
Group type: COMPARATOR
Intervention: Short-term tamoxifen treatment (2-3 years)
Number of subjects: 3793
Study 11032592 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term tamoxifen treatment (12-13 years) in node-positive patients
Number of subjects: 3793
Study 11032592 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term tamoxifen treatment (12-13 years) in estrogen receptor-positive patients
Number of subjects: 3793
Study 11032592 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term tamoxifen treatment (12-13 years) in estrogen receptor-negative patients
Number of subjects: 3793
Study 8772625 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propafenone, mean dose of 615 ± 10 mg day-1
Number of subjects: 48
Study 8772625 — intervention group
Group type: COMPARATOR
Intervention: Oral quinidine, mean dose of 1067 ± 462 mg day-1
Number of subjects: 48
Study 1482282 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (specific serotonin reuptake inhibitor)
Number of subjects: 15
Study 1482282 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (tricyclic antidepressant)
Number of subjects: 15
Study 1482282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3883971 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol hydrochloride 0.5%
Number of subjects: 42
Study 3883971 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol hydrochloride 1%
Number of subjects: 42
Study 3883971 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 42
Study 30473018 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific training program
Number of subjects: 144
Study 30473018 — intervention group
Group type: COMPARATOR
Intervention: Prescribed physical activity
Number of subjects: 144
Study 27000097 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartcoach (telephonic coaching every four weeks for six months)
Number of subjects: 374
Study 24108433 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX tool and pharmacist education on risks of low bone mass
Number of subjects: 87
Study 24108433 — intervention group
Group type: COMPARATOR
Intervention: Control group (heel ultrasound and pharmacist education without FRAX)
Number of subjects: 87
Study 22893497 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (SET) on top of best medical treatment (BMT) for 6 months
Number of subjects: 53
Study 22893497 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) only
Number of subjects: 53
Study 19224355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal moisturizer (VM) used during coital events for a 4 week period
Number of subjects: 40
Study 19224355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal microbicides
Number of subjects: 40
Study 19224355 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporating men into microbicide promotion efforts
Number of subjects: 40
Study 18317710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention during the last half of pregnancy
Number of subjects: 31
Study 18317710 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 31
Study 15665713 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine coadministered with 7vPn vaccine
Number of subjects: 345
Study 15665713 — intervention group
Group type: COMPARATOR
Intervention: DTPa-HBV-IPV/Hib vaccine alone
Number of subjects: 345
Study 12043288 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Fiber Analyser (NFA)
Number of subjects: 0
Study 12043288 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph (HRT)
Number of subjects: 0
Study 12043288 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 0
Study 10442525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 14
Study 10442525 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine 20 mg
Number of subjects: 14
Study 10442525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 14
Study 10442525 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 14
Study 10442525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg
Number of subjects: 14
Study 10442525 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 14
Study 10442525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7598141 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography
Number of subjects: 30
Study 7598141 — intervention group
Group type: COMPARATOR
Intervention: Contrast venography
Number of subjects: 30
Study 7598141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 30
Study 2242793 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 suppositories 2.5 mg 1‐2 a day
Number of subjects: 91
Study 2242793 — intervention group
Group type: COMPARATOR
Intervention: i.v. oxytocin 4‐32 mU/min
Number of subjects: 91
Study 321170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (iron dextran, 100 mg elemental iron)
Number of subjects: 0
Study 321170 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (ferrous sulphate, 100 mg elemental iron)
Number of subjects: 0
Study 31741350 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond laser treatment
Number of subjects: 10
Study 31741350 — intervention group
Group type: COMPARATOR
Intervention: Lightening cream (control)
Number of subjects: 10
Study 29268740 — intervention group
Group type: EXPERIMENTAL
Intervention: GABAergic stimulation
Number of subjects: 0
Study 29268740 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-2-adrenergic antagonism
Number of subjects: 0
Study 29268740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25775435 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 35
Study 25775435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 23860050 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (mean time of first oral feeding 2.5 + 0.7 days)
Number of subjects: 0
Study 23860050 — intervention group
Group type: COMPARATOR
Intervention: Late feeding (mean time of first oral feeding 5.3 + 0.6 days)
Number of subjects: 0
Study 23860050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (no mortality reported)
Number of subjects: 0
Study 21869636 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobble board balance training for 9 weeks, twice a week
Number of subjects: 23
Study 19700345 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 110
Study 19700345 — intervention group
Group type: COMPARATOR
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 110
Study 17721777 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon graft (group H)
Number of subjects: 96
Study 17721777 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone‐patellar tendon‐bone graft (group B)
Number of subjects: 96
Study 17721777 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 96
Study 10642363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise with vascular occlusion
Number of subjects: 6
Study 10642363 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity resistance exercise without occlusion (control)
Number of subjects: 6
Study 8857654 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g fluoride dentifrice
Number of subjects: 10
Study 8857654 — intervention group
Group type: COMPARATOR
Intervention: 1.0 g fluoride dentifrice
Number of subjects: 10
Study 1380721 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 22
Study 1380721 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 22
Study 1380721 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem and Iloprost
Number of subjects: 22
Study 1380721 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 6303690 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/hr device
Number of subjects: 15
Study 6303690 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/hr device
Number of subjects: 15
Study 31444036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 267
Study 31444036 — intervention group
Group type: COMPARATOR
Intervention: fMRI measures
Number of subjects: 267
Study 31444036 — intervention group
Group type: COMPARATOR
Intervention: Differential fear conditioning
Number of subjects: 267
Study 31444036 — intervention group
Group type: COMPARATOR
Intervention: Differential fear learning
Number of subjects: 267
Study 28548455 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 21
Study 28548455 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalization and professionalization of PSW role
Number of subjects: 21
Study 26775268 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-3-n-butylphthalide (NBP) for 30 days
Number of subjects: 170
Study 26775268 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic antiplatelet and lipid-lowering therapy only)
Number of subjects: 170
Study 23742103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVTA)
Number of subjects: 26
Study 23742103 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab
Number of subjects: 26
Study 22516525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic treatment (diet and fluid restriction)
Number of subjects: 648
Study 22516525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic treatment (daily weighing)
Number of subjects: 648
Study 22516525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic treatment (exercise)
Number of subjects: 648
Study 22516525 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational support
Number of subjects: 648
Study 22516525 — intervention group
Group type: EXPERIMENTAL
Intervention: New approaches to help patients stay physically active
Number of subjects: 648
Study 20200383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 453
Study 20200383 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 453
Study 20200383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 453
Study 18628451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine
Number of subjects: 0
Study 18628451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone as monotherapy
Number of subjects: 0
Study 18628451 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 0
Study 15952179 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic communication skills training program
Number of subjects: 58
Study 15952179 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic communication skills training program followed by consolidation workshops
Number of subjects: 58
Study 15952179 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' detection of patients' distress
Number of subjects: 58
Study 11836283 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE, 200 mg im weekly)
Number of subjects: 30
Study 11836283 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate plus depot medroxyprogesterone acetate (DMPA, 300 mg im once)
Number of subjects: 30
Study 11836283 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 men)
Number of subjects: 30
Study 10433577 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromatographically purified rabies vaccine (CPRV) 0.5 mL
Number of subjects: 400
Study 10433577 — intervention group
Group type: COMPARATOR
Intervention: Human diploid cell rabies vaccine (HDCV) 1.0 mL
Number of subjects: 400
Study 7672551 — intervention group
Group type: EXPERIMENTAL
Intervention: Large capacity biopsy forceps (needle version)
Number of subjects: 50
Study 7672551 — intervention group
Group type: EXPERIMENTAL
Intervention: Large capacity biopsy forceps (non-needle version)
Number of subjects: 50
Study 7672551 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle versions of each forceps
Number of subjects: 50
Study 7672551 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsy forceps (needle version)
Number of subjects: 50
Study 7672551 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsy forceps (non-needle version)
Number of subjects: 50
Study 7672551 — intervention group
Group type: EXPERIMENTAL
Intervention: Large capacity forceps
Number of subjects: 50
Study 2206065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mezlocillin for 48 hours followed by oral ampicillin until delivery
Number of subjects: 85
Study 2206065 — intervention group
Group type: COMPARATOR
Intervention: Intravenous and oral placebo
Number of subjects: 85
Study 31578073 — intervention group
Group type: EXPERIMENTAL
Intervention: careHPV
Number of subjects: 7138
Study 31578073 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 7138
Study 30413383 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 1220
Study 30413383 — intervention group
Group type: COMPARATOR
Intervention: Upfront debulking surgery
Number of subjects: 1220
Study 30413383 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (stage IV)
Number of subjects: 1220